Clinical Trials Logo

Anticoagulation clinical trials

View clinical trials related to Anticoagulation.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05305612 Enrolling by invitation - Atrial Fibrillation Clinical Trials

Optimal PeriproCeduraL AnticOagulation in Structural Transseptal Interventions

STOP CLOT
Start date: March 13, 2022
Phase: Phase 4
Study type: Interventional

The transcatheter edge to edge mitral valve repair (TEER) and left atrial appendage closure (LAAC) are the interventional cardiology procedures that require periprocedural anticoagulation with unfractionated heparin (UFH). The UFH is administered either before or immediately after transseptal puncture, at the discretion of the operator The aim of the study is to establish the optimal timing of initiation of periprocedural anticoagulation in patients undergoing structural heart interventions requiring transseptal puncture (TEER and LAAC), Patients who undergo TEER implantation or LAAC procedure will be randomized to two groups: 1. Early UFH administration. The iv. bolus of UFH (100Units/kg) will be given after obtained femoral vein access and at least 5 minutes prior to the start of the TSP. 2. Late UFH administration. The iv. bolus of UFH (100Units/kg) will be given immediately after TSP, defined as the introduction of transseptal sheath into the left atrium.